Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Accelerated development of malaria monoclonal antibodies
Journal
Cell Rep Med
Volume
3
Number
10
Pages
100786
Keywords
Adult; Humans; *Antimalarials/adverse effects; Antibodies, Monoclonal/adverse effects; *Malaria/drug therapy; *Antineoplastic Agents, Immunological; M.P. are funded by the Bill and Melinda Gates Foundation (INV-002562 to MAP) to; model Target Product Profiles of next-generation seasonal interventions.
Mesh terms
Adult; Humans; Antibodies, Monoclonal, adverse effects; Antimalarials, adverse effects; Malaria, drug therapy; Clinical Trials, Phase I as Topic
Abstract
L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.(1) These promising results are the first of many to usher in a potential new era of malaria prevention.
